An immunological comparison of third companion in advanced drug-naive HIV-infected patients

HIV Clinical Trials

Volumn 7, Issue 5, 2006, Pages 221-228

  Rizzardini, Giuliano ^a   Trabattoni, Daria ^b   Capetti, Amedeo ^a   Castelletti, Eleonora ^b   Migliorino, Marco ^c   Panebianco, Ruggero ^d   Pacei, Michela ^b   Quirino, Tiziana ^c   Clerici, Mario ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Department of Pathology Servizio di Anatomia Patologica Ospedale di Circolo   (Italy)

^d GSK   (Italy)

Author keywords

Advance na ve patients; Antiviral therapy; HIV; Immune modulation; Immunology; Third companion

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; MITOGENIC AGENT; PROTEINASE INHIBITOR; RITONAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL PARAMETERS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; VIREMIA;

EID: 33845688486     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0705-221     Document Type: Article

References (38)

1. d'Arminio Monforte A, Lepri Cozzi A, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS. 2000;14:499-507.
2. Bartlett JA, Fath MJ, DeMasi R, et al. An update systematic overview of triple combination therapies in antiretroviral naïve HIV infected adults. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, Massachusetts, USA. Abstract 586.
3. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
4. Gallant JE, Rodriguez AE, Weinberg W, et al. Early non response to tenofovir (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFZ) + ABC and 3TC: ESS 30009 unplanned interim analysis. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL. Abstract H1722a.
5. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. New Engl J Med. 2004;350:1850-1861.
6. Jemsek J, Hutchereson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naïve, HIV infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine and tenofovir TDF. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, CA, USA. Abstract 51.
7. Kirkland LR, Fischl MA, Tashima KT, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis. 2002;34:511-518.
8. Landman R, Peytavin G, Descamps D, et al. Low genetic barrier to resistance is a possible cause of early virologic failure in once-daily regimen of abacavir, lamivudine and tenofovir: the TONUS study. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, CA, USA. Abstract 52.
9. Seaton RA, Fox R, Bodasing N, Peters SE, Gourlay Y. Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection. AIDS. 2003:17:445-453.
10. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. New Engl J Med. 2004;350:1850-1861.
11. Gulick R. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents. AIDS. 1998;12(suppl 3):S17-22.
12. Fauci AS. Immunopathogenic mechanisms of HIV infection. Ann Int Med. 1996,124:654-663.
13. Gorochov G, Neumann AU, Parizot C, Li T, Katlama C, Debré P. Down-regulation of CD8+ T cell-expansions in patients with HIV infection receiving highly active combination therapy. Blood. 2001,97:1787-1795.
14. Appay V, Nixon DF, Donahoe SM, et al. HIV-specific CD8+ T cells produce antiviral cytokines but are impaired in cytolitic function. J Exp Med. 2000:192:63-75.
15. Trabattoni D, Piconi S, Biasin M, et al. Granule-dependent mechanisms of lysis are defective in CD8+ T cells of HIV-infected, antiviral therapy-treated individuals. AIDS. 2004;18:859-869.
16. Clerici M, Stocks NI, Zajac RA, et al. IL-2 production permits detection of antigenic peptide recognition by T helper lymphocytes from asymptomatic, HIV seropositive individuals. Nature. 1989;339:383-385.
17. DeLisi C, Berzofsky JA. T cell antigenic sites tend to be amphipathic structures. Proc Natl Acad Sci (USA). 1985:82:7048-7052.
18. Trabattoni D, Lo Caputo S, Biasin M, et al. Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients. Clin Diagn Lab Immunol. 2002;9(5):1114-1118.
19. Angel JAB, Kumar A, Parato A, et al. Improvement in cell-mediated immune function, during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis. 1998;177:898-904.
20. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116.
21. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations of the immune response of HIV-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis. 1996;173:321-329.
22. Giorgi JV, Majchrowicz MA, Johnson TD, Hultin P, Matud J, Detels R. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS. 1998;12:1833-1844.
23. Weiss L, Burgard M, Cahen YD, et al. Immunological and virological features of HIV-infected patients with increasing CD4 cell numbers despite virological failure during protease inhibitor-based therapy. HIV Med. 2002;3:12-20.
24. Barreiro P, Soriano V, Casas E, Gonzalez-Lahoz J. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS. 2002;25:245-249.
25. Benito JM, Lopez M, Martin JC, et al. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors. AIDS Res Hum Retrovir. 2002;18:1379-1388.
26. Piconi S, Trabattoni D, Fusi ML, et al. Effect of two different combinations of antiretrovirals (AZT+ddl and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection. Antiviral Res. 2000;46:171-179.
27. Arribas JR, Pulido F, Miro JM, et al. High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients). AIDS. 2002;16:1554-1556.
28. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. JAIDS. 2004;35:22-32.
29. Pulido F, Arribas JR, Miro JM, et al. Clinical, virologic, and immunologic response to efavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). JAIDS. 2004;35:343-350.
30. Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS. 2004;18:1529-1537.
31. Rosenblatt HM, Stanley KE, Song LY, et al. Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection. J Infect Dis. 2005;192:445-455.
32. Lange CG, Lederman MM, Madero JS, et al. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. JAIDS. 2002;30:33-40.
33. Saag MS. The impact of highly active antiretroviral therapy on HIV-specific immune function. AIDS. 2001;15:S4-S10.
34. Lederman MM. Immune restoration and CD4+T-cell function with antiretroviral therapies. AIDS. 2001;15:S11-S15.
35. Lederman MM, Valdez H. Immune restoration with antiretroviral therapies - implications for clinical management. JAMA. 2000;284:223-228.
36. Cooper DA. Immunological effects of antiretroviral therapy. Antiviral Ther. 1998;3:19-23.
37. Shaefer MS. Abacavir/Lamivudine/Zidovudine continues to be a valid and useful antiretroviral regimen. Annals Pharmacother. 2004;38:1314-1316.
38. Kessler HA. Triple-nucleoside analog antiretroviral therapy: Is there still a role in clinical practice? A review. MedGenMed. 2005;7:70.